A Review of Triple-Negative Breast Cancer
Open Access
- 1 July 2010
- journal article
- review article
- Published by SAGE Publications in Cancer Control
- Vol. 17 (3), 173-176
- https://doi.org/10.1177/107327481001700305
Abstract
Background An estimated 1 million cases of breast cancer are diagnosed annually worldwide. Of these, more than 170,000 are described as triple-negative. Triple-negative breast cancer (TNBC) is defined by the lack of protein expression of estrogen receptor (ER) and progesterone receptor (PR) and the absence of HER2 protein overexpression. TNBC is a subtype of breast cancer that overlaps with the “basal-like” breast cancer. TNBC has significant clinical implications. Methods The epidemiology, diagnosis, clinical course, prognosis, and pathology of this subtype of breast cancer are reviewed. The authors compare the “triple-negative” and “basal-like” definitions of breast cancer. A discussion of both standard and experimental treatments for TNBC is included. Results The poor prognosis of high-grade TNBC relates to poor disease-free interval in the adjuvant setting, shortened progression-free survival in the metastatic setting, and the lack of targeted therapy. However, not all TNBCs are associated with a poor prognosis. Conclusions Although chemotherapy is the main current treatment of this subtype of breast cancer, new agents such as PARP inhibitors, which show promise in the treatment of TNBC, are currently in clinical trials.Keywords
This publication has 24 references indexed in Scilit:
- Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast CancerClinical Breast Cancer, 2009
- Gene-Expression Signatures in Breast CancerNew England Journal of Medicine, 2009
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences of the United States of America, 2008
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJama-Journal Of The American Medical Association, 2006
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences of the United States of America, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001